Accuray Incorporated (ARAY)vsEdwards Lifesciences Corp (EW)
ARAY
Accuray Incorporated
$3.08
-3.75%
HEALTHCARE · Cap: $16.72M
EW
Edwards Lifesciences Corp
$105.80
-0.01%
HEALTHCARE · Cap: $59.81B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1561% more annual revenue ($6.67B vs $401.95M). EW leads profitability with a 15.3% profit margin vs -12.2%. EW appears more attractively valued with a PEG of 2.14. EW earns a higher WallStSmart Score of 54/100 (C-).
ARAY
Hold37
out of 100
Grade: F
EW
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARAY.
Margin of Safety
+69.2%
Fair Value
$257.48
Current Price
$105.80
$151.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Strong operational efficiency at 30.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
Trading at 8.8x book value
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ARAY
ARAY has a balanced fundamental profile.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : ARAY
The primary concerns for ARAY are Price/Book, Market Cap, Piotroski F-Score. Debt-to-equity of 2.56 is elevated, increasing financial risk.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.
Key Dynamics to Monitor
ARAY profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.
ARAY carries more volatility with a beta of 1.42 — expect wider price swings.
EW is growing revenue faster at 10.5% — sustainability is the question.
EW generates stronger free cash flow (507M), providing more financial flexibility.
Bottom Line
EW scores higher overall (54/100 vs 37/100), backed by strong 15.3% margins and 10.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Accuray Incorporated
HEALTHCARE · MEDICAL DEVICES · USA
Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?